Celesio AG / Joint Venture
21.06.2010 08:33
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Celesio and Medco Announce Pan-European Joint Venture to Enhance Quality of
Clinical Care and Reduce Overall Healthcare Costs
Celesio and Medco, two of the world's leading pharmacy-driven healthcare
companies, today announced a joint venture with a long-term goal of
improving the quality of patients' healthcare through integrated solutions
and relieving the financial burden on healthcare payors across Europe.
Headquartered in Amsterdam, the 50/50 joint venture, Medco Celesio B.V.,
combines Medco and Celesio's strengths in pharmacy-driven clinical care.
Medco Celesio B.V. is designed to help patients with chronic or complex
conditions, such as diabetes, asthma, high-cholesterol and heart disease.
It will concentrate on innovative, integrated clinical services designed to
improve patient adherence - meaning following doctors orders - integrate
care across multiple providers, and enhance safety and efficiency across
the healthcare system.
The joint venture will go into operation initially in Germany in 2010,
including the collaboration of the parent companies' respective mail order
pharmacies, DocMorris and Europa Apotheek Venlo. It will then extend
rapidly in phases to the major European markets, including the U.K.,
France, Spain and Italy. Over time, it is planned to expand its geographic
footprint into as many as 27 EU member states plus Switzerland and Norway.
The joint venture will cooperate closely with health policymakers, funding
bodies, pharmacies, healthcare providers and their umbrella organizations,
producers of pharmaceuticals, patients' associations and leading research
institutes.
Contacts:
Investor Relations
Thomas Frings, Celesio AG, +49 (0)711.5001-532
investor@celesio.com
Media
Dr. Jens Schreiber, Celesio AG, +49 (0)711.5001-380
media@celesio.com
---------------------------------------------------------------------------
Information and Explaination of the Issuer to this News:
- Combines capabilities of two of the world's leading pharmacy-driven
healthcare companies
- Joint Venture focuses on advancing the efficiency of pharmacy through
integrated solutions to improve care for patients with chronic and
complex health conditions
- Supports payors, patients, pharmacists and physicians
- Joint-Venture will reduce overall healthcare costs while delivering
significant improvements in healthcare quality
- Important strategic step for both Celesio and Medco to speed entry into
new markets and market segments with high-growth potential
21.06.2010 08:33 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv at |[![CDATA[|[a href="http://www.dgap-medientreff.de"|]www.dgap-medientreff.de|[/a|]]]|] and |[![CDATA[|[a href="http://www.dgap.de"|]www.dgap.de|[/a|]]]|]
---------------------------------------------------------------------------
Language: English
Company: Celesio AG
Neckartalstr. 155
70376 Stuttgart
Deutschland
Phone: +49 (0)711 5001-735
Fax: +49 (0)711 5001-736
E-mail: investor@celesio.com
Internet: www.celesio.com
ISIN: DE000CLS1001
WKN: CLS100
Indices: MDAX
Listed: Regulierter Markt in Berlin, Frankfurt (Prime Standard),
München, Düsseldorf, Stuttgart; Freiverkehr in Hannover,
Hamburg; Terminbörse EUREX
End of News DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: Celesio AG: Celesio and Medco Announce Pan-European Joint Venture to Enhance Quality of Clinical Care and Reduce Overall Healthcare Costs
| Source: EQS Group AG